Fleur Mauritz MD; EBCC 2026: RAPCHEM Study Shows Risk-Based Radiotherapy De-Escalation is Safe After Primary Systemic Therapy for Early Breast Cancer

episode

Audio Journal of Oncology Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

The Songs of John Farnham: A Living Legend | Tony Cochrane (23.09.26) 7 min · 23 Sep 2026 · Whateley

Las 10 de Erazno, el Chokolatazo, Parodias, 1h 29m · 23 Sep 2026 · Erazno y La Chokolata El Podcast

Steve Hilton & Spencer Pratt: Fixing California, Cheaper Gas, Ballot Fraud & CA Republicans 55 min · 23 Sep 2026 · All-In with Chamath, Jason, Sacks & Friedberg

Optics of Alastair Clarkson's brunt sacking | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

The Eminently Sensible Phil Davis | Whateley (23.09.26) 13 min · 23 Sep 2026 · Whateley

The impact of Zak Butters' homecoming | The Eminently Sensible Phil Davis (23.09.26) 1 min · 23 Sep 2026 · Whateley

Report any issue

Source

Recorded03 Apr 2026

Publisheraudiomedica.com ↗

Handlerec:19315667

Show notes

Fleur Mauritz MD discusses the 10-year follow-up findings from the RAPCHEM study, presented at the EBCC 2026. The research indicates that risk-based radiotherapy de-escalation is safe and effective following primary systemic therapy for early breast cancer patients. This approach allows for tailored treatment, potentially reducing side effects without compromising low recurrence rates. The study provides crucial long-term evidence supporting individualized radiotherapy strategies.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in